Word abonnee en neem Beursduivel Premium
Rode planeet als pijlen grid met hoorntjes Beursduivel
Uitgebreid zoeken
Aandeel

VALERIO TX FR0010095596

Laatste koers (eur)

0,116

  • Verschill

    +0,002 +1,75%

  • Volume

    132.922 Gem. (3M) 81K

  • Bied

    -  

  • Laat

    -  
+ Toevoegen aan watchlist

Onxeo 2020

84 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste | Omlaag ↓
  1. forum rang 4 RW1963 28 februari 2020 15:13

    • RW1963

      Lid sinds: 16 apr 2015

      Laatste bezoek: 27 apr 2024

    • Aanbevelingen

      Ontvangen: 1324

      Gegeven: 9933

    •    Aantal posts: 6.301

    quote:

    rationeel schreef op 28 februari 2020 14:21:

    [...]

    Hier is de aanleiding voor het pb:

    today announces that the Company will... present... first preclinical results on OX401,... its... next-generation... PARP inhibitor (PARPi),... during a poster session at the... ESMO-TAT1 Congress 2020 ...dedicated to the research on targeted cancer therapies, to be held in... Paris, France,... on... March 2-4, 2020...

    Daar ontmoeten ze elkaar, en kunnen misschien zaken doen;)
    Bedankt, maar zoals ik al zei vind ik het knap lastig al die Engelse (technische) teksten te lezen.

    Ach ja, als het paar positief is.

    Welke bedrijven noemde jij in het Corona-verhaal? Niet dat ik ze kopen wil (heb mijn neus al een paar keer flink gestoten), maar wil wel meekijken.

  3. forum rang 10 rationeel 27 maart 2020 21:47

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 07 jun 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    Paris (France), February 27, 2020 – 5:45 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, today announces the postponement of the publication of its 2019 full-year results until April 17, 2020, after the close of trading.

    Indeed, due to the constraints imposed by the current context, the meeting of the Board of Directors to close the accounts, which was scheduled for March 31, 2020, has been postponed to April 17, 2020. As a result, the Combined General Meeting, initially scheduled to be held on May 13, 2020, is postponed to May 29, 2020.
  4. forum rang 4 RW1963 9 april 2020 09:44

    • RW1963

      Lid sinds: 16 apr 2015

      Laatste bezoek: 27 apr 2024

    • Aanbevelingen

      Ontvangen: 1324

      Gegeven: 9933

    •    Aantal posts: 6.301

    Het wordt tijd dat dit aandeel ook eens een sprong voorwaarts gaat maken zoals sommige aandelen dat ook doen in deze Corona-tijd ;-)
  7. forum rang 10 rationeel 15 april 2020 15:53

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 07 jun 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    Onxeo : to Receive $6.6 Million by Granting Additional Exclusive Rights to Belinostat to Acrotech Biopharma LLC

    > This transaction completes Onxeo’s strategic transition to a company solely focused on DNA Damage Response (DDR) activities in oncology
    > $6.6m received from Acrotech extends Onxeo’s cash runway into Q2 2021 and supports Company’s DDR-related programs
  8. forum rang 10 rationeel 15 april 2020 17:00

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 07 jun 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808


    INVITATION

    To mark the publication of its 2019 Full Year Results, the management team of Onxeo is pleased to invite you to a conference call on:

    Friday, April 17, 2020 at 6:15 pm CEST

    followed by a Q&A session.

    The call will be accessible via the below conference call details:

    France: +33 1 72 72 74 03
    United States: +1 646 7224 916
    United Kingdom: +44 20 71943 759
    Denmark: +458 23 33 187

    PIN code: 47169541#

    You can also follow the slideshow presentation on the web:

    www.anywhereconference.com?Conference...
  9. forum rang 4 RW1963 15 april 2020 17:45

    • RW1963

      Lid sinds: 16 apr 2015

      Laatste bezoek: 27 apr 2024

    • Aanbevelingen

      Ontvangen: 1324

      Gegeven: 9933

    •    Aantal posts: 6.301

    quote:

    rationeel schreef op 15 april 2020 15:14:

    Boven 0,5306 blijven dan is het aandeel uit het dalende kanaal.
    Net aan gelukt ;-)

    Kom nu maar op. Lang genoeg gewacht.
  11. forum rang 4 RW1963 24 april 2020 19:26

    • RW1963

      Lid sinds: 16 apr 2015

      Laatste bezoek: 27 apr 2024

    • Aanbevelingen

      Ontvangen: 1324

      Gegeven: 9933

    •    Aantal posts: 6.301

    quote:

    rationeel schreef op 17 april 2020 14:32:

    Bijna ob.

    Prettig wanneer het aandeel vervolgens bij het retracen boven de 51,09...46,86 blijft.
    Ver eronder !
  12. forum rang 10 rationeel 27 april 2020 15:42

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 07 jun 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    50% retracement op de dag...0,4575.

    0,514 bovenkant neerwaartse kanaal. Zit hij nu weer tegenaan:(

    Indien het aandeel boven de 0,4575 de nieuwe bodem zet, dan kan deze weerstand overwonnen worden.

    Houd goede moed:)

  13. forum rang 10 rationeel 19 mei 2020 19:16

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 07 jun 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    Paris (France), May 19, 2020 – 5:45 pm CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced the presentation of preclinical data supporting the differentiated ability of AsiDNA™, its first-in-class DNA Damage Response (DDR) inhibitor, to reverse resistance to PARP inhibitors (PARPi) by preventing death-tolerant cells (DTC) regrowth. These promising results will be presented in an e-posters session during the American Association for Cancer Research (AACR) annual meeting which, given the COVID-19 context, will be held virtually on June 22-24, 2020.

    Françoise Bono, PhD, Chief Scientific Officer of Onxeo, commented: "We continue to strengthen our understanding of AsiDNA™'s unique mechanism of action and have generated new data demonstrating its ability to specifically target drug-tolerant or persistent tumor cells that result in resistance to targeted therapies, and in particular, as we are demonstrating for the first time in this study, resistance to PARP inhibitors. We are delighted to be able to present at this prestigious oncology-focused meeting this new study on the effect of AsiDNA™ on these persistent cells when combined with PARP inhibitors. These results add to AsiDNA™'s strong preclinical file, reinforce the legitimacy of its current development in the clinical setting and confirm its interest and value in our Company's portfolio.”

    These new data show for the first time that PARPi resistance can be caused by drug-tolerant cells, and that the addition of AsiDNA™ to PARP inhibitors prevents the regrowth of these cells, thereby completely and irreversibly abolishing the emergence of resistance in ovarian tumor cells.

    The results from this study are extremely encouraging for the upcoming Phase 1b/2 REVocan study, combining AsiDNA™ with niraparib in the clinical setting in recurrent ovarian cancer, which is expected to start in the second half of 2020. These data clearly reinforce AsiDNA™'s interest in the fight against resistance, which is the main challenge in cancer treatment today.

    Session: PO.ET03.04 - Mechanisms of sensitivity and resistance to DNA damage repair targeting
    Date/ Time: June 22, 2020 - 9:00 AM - 6:00 PM (U.S. Eastern Daylight Time -EDT)
    E-poster: 4078 / 8

    Click on this link to read the abstract: Acquired resistance to PARP inhibitors evolves from drug-tolerant persister cells vulnerable to AsiDNA™.


    About Onxeo
    Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

    platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

    AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

    OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

    www.onxeo.com
  14. forum rang 10 rationeel 27 mei 2020 12:07

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 07 jun 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation


    The press release in PDF

    Paris (France), May 27, 2020 – 8:45 am CEST – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, today announced the publication of an initiation report by Bryan Garnier & Co, a leading independent European financial services company specialized in research, execution and advisory services.

    Bryan Garnier & Co. will now follow Onxeo's share price on the Euronext Paris stock exchange* and values the Company at 1.22 euro per share*.

    For more information: www.bryangarnier.com ou drayot@bryangarnier.com (Head of Corporate Sales).

    * This information does not constitute an offer to sell or subscribe, or the solicitation of an order to buy or subscribe for securities in France, Europe, the US or any other country. Onxeo and Bryan Garnier & Co have agreed on a service for the production and distribution of financial analyses.

    About Bryan Garnier & Co
    Bryan, Garnier & Co is a European, full-service growth-focused independent investment banking partnership founded in 1996. The firm provides equity research, sales and trading, private and public capital raising as well as M&A services to growth companies and their investors. It focuses on key growth sectors of the economy including Technology, Healthcare, Consumer and Business Services. Bryan, Garnier & Co is a fully registered broker dealer authorized and regulated by the FCA in Europe and the FINRA in the U.S. Bryan, Garnier & Co is headquartered in London, with additional offices in Paris, Munich, Stockholm, Oslo and Reykjavik as well as New York and Palo Alto. The firm is a member of the London Stock Exchange.


    About Onxeo
    Onxeo (Euronext Paris, NASDAQ Copenhagen: ONXEO) is a clinical-stage biotechnology company developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response (DDR). The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.

    platON™ is Onxeo’s proprietary chemistry platform of oligonucleotides acting as decoy agonists, which generates new innovative compounds and broaden the Company’s product pipeline.

    AsiDNA™, the first compound from platON™, is a first-in-class, highly differentiated DNA Damage Response (DDR) inhibitor based on a decoy and agonist mechanism acting upstream of multiple DDR pathways. Translational research has highlighted the distinctive properties of AsiDNA™, notably its ability to abrogate tumor resistance to PARP inhibitors regardless of the genetic mutation status. AsiDNA™ has also shown a strong synergy with other tumor DNA-damaging agents such as chemotherapy and PARP inhibitors. The DRIIV-1 (DNA Repair Inhibitor-administered IntraVenously) phase I study has evaluated AsiDNA™ by systemic administration (IV) in advanced solid tumors and confirmed the active doses as well as a favorable human safety profile. The ongoing DRIIV-1b extension study is assessing the safety and efficacy of a 600 mg dose of AsiDNA™ in combination with carboplatin and then with carboplatin and paclitaxel, in patients with solid tumors who are eligible for such treatments.

    OX401 is a new drug candidate from platON™, optimized to be a next-generation PARP inhibitor acting on both the DNA Damage Response and the activation of immune response, without inducing resistance. OX401 is undergoing preclinical proof-of-concept studies, alone and in combination with immunotherapies.

    www.onxeo.com
  16. forum rang 4 RW1963 27 mei 2020 17:19

    • RW1963

      Lid sinds: 16 apr 2015

      Laatste bezoek: 27 apr 2024

    • Aanbevelingen

      Ontvangen: 1324

      Gegeven: 9933

    •    Aantal posts: 6.301

    Zeer mooie stijging vandaag.
    Wat te doen?
    Zal het verder stijgen of komt er weer een omslagpunt?
    Ik sta nog lang niet Breakeven.
  17. forum rang 10 rationeel 27 mei 2020 18:54

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 07 jun 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    Ik ook niet. Maar nu heb ik toch spijt niet op die laagste prijs te hebben bijgekocht.

    Is de stijging omdat Bryan Garnier & Co initiates the coverage of Onxeo with a “Buy” recommendation,
    of omgekeerd, omdat ze zo goed gaan, heeft Bryan Garnier & Co zin om te gaan volgen en koop aanbevelingen af te geven.

    Hij had in ieder geval goedkoop kunnen inslaan;)
  18. forum rang 10 rationeel 27 mei 2020 19:25

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 07 jun 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    Laatste ...*** 0,837***... 17:39:50 Theor. open 0,837 17:35:10
    Bied 0,82 17:40:01 Laat 0,84 17:40:05
    Laagste ...***0,512***... 09:00:23 Hoogste ...***0,862***... 15:57:00
    Open 0,518 09:00:23 Vorig slot 0,4905 26-05-20
    Cum. vol...***9.310.474***... Gem. dagomzet ...***269.348***...

    Een plus van 70,64%
  20. forum rang 10 rationeel 28 mei 2020 13:00

    • rationeel

      Lid sinds: 07 okt 2004

      Laatste bezoek: 07 jun 2024

    • Aanbevelingen

      Ontvangen: 22854

      Gegeven: 1806

    •    Aantal posts: 65.808

    quote:

    voorschoten schreef op 28 mei 2020 09:35:

    Ooit voor € 1,- gekocht.
    En maar zakken, zakken.
    Gaat het nog wat worden ?
    Lachen hoor.
    Ja, het kon nog veel lager.

    Maar het zal het laatste aandeel in de biotechnologie niet zijn, dat ook nog weer veel hoger bleek te kunnen.

    En dar hopen we dan maar op:)
84 Posts
Pagina: «« 1 2 3 4 5 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beursduivel.be

Al abonnee? Log in
Premium

Benieuwd naar onze analyses en kooptips?

Word nu abonnee van BeursDuivel en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 55% korting!

Word abonnee

Laatste Nieuws

  1. Wall Street licht lager gesloten
  2. Consumentenkrediet VS gestegen
  3. Olieprijs sluit vrijwel vlak
  4. Europese beurzen lager gesloten
  5. Klein verlies na sterk banenrapport VS
  6. Beursagenda: Belgische bedrijven
  7. Amerikaanse groothandelsvoorraden licht gestegen
  8. Wall Street koerst af op lagere opening
  9. Beursblik: banenrapport VS bron van zorg voor Powell
  10. Amerikaanse banengroei veel sterker dan verwacht
  11. Bel20 richtingloos in aanloop naar Amerikaans banenrapport
  12. GameStop wil 75 miljoen aandelen verkopen

Meest Gelezen Premium

  1. Premium Premium
    Deze 12 smallcappers zijn klaar voor hun langverwachte inhaalslag
  2. Premium Premium
    De markt kijkt niet verder dan zijn neus lang is bij Pharming
  3. Premium Premium
    Waarom Ahold Delhaize interessant is ondanks weinig verrassende doelen
  4. Premium Premium
    Koersdoel ASML met 25% verhoogd
  5. Premium Premium
    Vooruitblik: olie, ECB en banen domineren loeispannende beursweek
  6. Premium Premium
    Nvidia keurt Samsung-chips af en Micron is de lachende derde
  7. Premium Premium
    Koersstijging Chinese tech-gigant Tencent (+25%) steunt aandeel Prosus

Macro & Bedrijfsagenda

  1. 10 juni

    1. NL industriële productie april
    2. FuelCell Q2-cijfers

  2. 11 juni

    1. NL inflatie mei def.
    2. VK werkloosheid april
    3. VS ondernemersvertrouwen MKB mei
    4. Eurocommercial Properties AvA
    5. Maandrapport OPEC
de volitaliteit verwacht indicator betekend: Market moving event/hoge(re) volatiliteit verwacht
Naar de hele agenda